PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Cytarabine

Drugs in development · updated 30 October 2026

Cytarabine: clinical trials and development status

Other names and codes: Ara-C, Cytosine Arabinoside, Depocyt

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 11 July 2001

As of 30 October 2026 Cytarabine is in 236 active clinical trials (recruiting or ongoing, phases I–III) for 56 diseases. The most advanced phase is III.

236Active trials
IIIMost advanced phase
56Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Cytarabine and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 56 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Acute myeloid leukemiaIII109NCT07132684
Precursor lymphoblastic lymphoma/leukemiaIII32NCT03007147
Burkitt lymphomaIII21NCT02101853
Acute biphenotypic leukaemiaIII19NCT03007147
Myelodysplastic SyndromesIII19NCT02521493
LeukemiaIII14NCT07007312
Precursor T-cell lymphoblastic leukemiaIII11NCT02112916
Precursor B-cell lymphoblastic leukemiaIII10NCT03914625
LymphomaII–III6NCT07072585
Non-Hodgkin lymphomaIII6NCT06230224
Hematologic neoplasmIII5NCT07007312
Myeloproliferative disordersIII5NCT02521493
Down syndromeIII4NCT03914625
Langerhans-cell histiocytosisIII4NCT02670707
Residual neoplasmIII4NCT02724163
B-cell lymphomaIII3NCT07739654
Multiple myelomaIII1NCT06520176
Mantle cell lymphomaII12NCT07763210
Chronic myelomonocytic leukemiaII6NCT03418038
Diffuse large B-cell lymphomaII6NCT02570542
Blast CrisisII5NCT01424982
Hodgkin lymphomaII5NCT03418038
T-cell lymphomaII4NCT06390319
Accelerated phase chronic myelogenous leukemiaII3NCT01424982
Follicular lymphomaII3NCT03125642
Myeloid sarcomaII3NCT03589729
Acute monocytic leukemiaII2NCT06504459
Acute myelomonocytic leukemiaII2NCT00801489
Blastic plasmacytoid dendritic cell neoplasmII2NCT04216524
Juvenile myelomonocytic leukemiaI–II2NCT05849662

Everything on Cytarabine

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch